Tern Plc cuts Board pay and introduces shareholder distribution policy

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced a reduction in the fixed remuneration of Tern’s board and its executive management, together with a distribution commitment for when significant proceeds are received from exits of the Company’s investments.

As previously announced, the focus of the Board and Tern’s executive management team is on realisations and specifically seeking to maximise the value that can be realised from Tern’s portfolio companies and investments through successful exits from its investments at the appropriate time, ultimately seeking strong returns for shareholders.  At the same time the Company is maintaining strict control over operational costs and looking to make further savings where appropriate, in addition to the significant savings made in 2024 and the current financial year.

The Board have examined ways in which the operational costs of the Company can be further reduced, whilst aligning the interests of Tern’s Board and executive management with those of shareholders.  The Board, with the agreement of the executive management, have therefore resolved that:

·    Fixed remuneration reduction: From 1 November 2025 there will be a 50 per cent reduction in the salaries of the two Board directors, Jane McCracken and Iain Ross, and Tern’s executive managers Al Sisto and Bruce Leith.  This is expected to provide a saving of approximately £153,000 on an annualised basis.

·    Performance-aligned remuneration policy: The Board has adopted a remuneration policy whereby 12.5% of the net proceeds of any exit of the Company’s investments will be allocated to the executive team and Board, being those directly responsible for the Company’s capital allocation, strategy, and execution.

·    Shareholder distribution commitment: The Board has committed that shareholders will receive a distribution or capital return of at least 50% of the net proceeds received by the Company from the exit of any individual investment over £1 million (subject to the Company having sufficient distributable reserves and no legal or regulatory impediment to undertaking such an action).  

Commenting, Jane McCracken, Interim Non-Executive Chair of Tern, said: “We recognise that it is very important that management and shareholder interests are aligned, particularly during this capital-intensive phase of development of Tern’s investments.  The decision to reduce Board and executive management salaries by 50% will only have a modest financial impact on Tern, but coupling this with a fixed performance-based component of remuneration reflects our desire to signal a clear alignment of interests with shareholders.  This is not a discretionary bonus scheme, but a lean, outcome-driven policy designed to reflect the team’s scale of responsibility and the nature of our mandate.

“Our focus remains on realisations and we wish to give shareholders a clearer indication of what they can expect when we receive proceeds from exiting investments.  The Tern Board and management team are all working hard to deliver shareholder value and I look forward to providing further updates in due course.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Search